The company has completed the acquisition of Amishi Drugs & Chemicals (AD&C), and the securing of a majority position on Mannitab Pharma Specialities
Ingredion, a leading global provider of ingredient solutions has completed two strategic investments in India to expand into high-value pharmaceutical applications.
“These investments are part of our strategy to expand our specialty pharmaceutical product portfolio to better serve our customers and diversify into high-value nonfood adjacencies,” said Jim Zallie, Ingredion’s President and CEO.
As a result of these strategic investments, the Company’s portfolio of functional excipients now includes binders, fillers, superdisintegrants, lubricants, gelatine replacers for softgels, viscosifiers, encapsulation materials, and parenteral grade dextrose. The company manufactures these highly functional materials under stringent pharma Good Manufacturing Practices (GMPs) and supports its customers with regulatory expertise and collaborative technical support.
“Ingredion looks forward to partnering with pharma and nutraceutical formulators and helping them meet regulatory challenges, progress drug development, and identify emerging trends,” added Rana Kayal, Global Director for Pharma & Nutraceuticals.